Spruce Biosciences. has filed a patent for a method of treating polycystic ovary syndrome (PCOS) with elevated adrenal androgens. The patent claims the use of a CRF1 antagonist or its salt for treating PCOS in patients with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism. This new compound could potentially provide a novel treatment option for PCOS patients. GlobalData’s report on Spruce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spruce Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Spruce Biosciences's grant share as of September 2023 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230295161A1) describes a method for treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH+FAH) using a CRF1 antagonist or a pharmaceutically acceptable salt thereof. The method involves administering the CRF1 antagonist to a subject in need of treatment.
The patent claims specify that the CRF1 antagonist can be a compound of Formula (I), and provides a list of specific compounds that can be used as CRF1 antagonists, including Antalarmin hydrochloride, CP-154,526, CP-376395 hydrochloride, NBI 27914 hydrochloride, NBI 35965 hydrochloride, NGD 98-2 hydrochloride, Pexacerfont, R 121919 hydrochloride, SSR125543 (crinecerfont), and SN003.
The patent also provides various dosage options for administering the CRF1 antagonist or pharmaceutically acceptable salt to the subject. The dosage ranges from about 5 mg to about 400 mg total daily dose, with specific doses mentioned such as 300 mg, 200 mg, 150 mg, 100 mg, 75 mg, 50 mg, 25 mg, and 10 mg total daily dose.
Furthermore, the patent claims that the method of treatment results in a reduction of certain hormone levels. For example, the method can reduce adrenocorticotropic hormone (ACTH) levels by at least 10% from baseline, reduce dehydroepiandrosterone sulfate (DHEAS) levels from baseline, reduce androstenedione (A4) levels by at least 10% from baseline, reduce 1ß-hydroxyandrostenedione (11OHA4) levels by at least 10% from baseline, and reduce 11ß-hydroxytestosterone (11OHT) levels by at least 10% from baseline. The reduced hormone levels are maintained for at least 24 hours.
The patent also mentions that the pharmaceutical composition containing the CRF1 antagonist can be in the form of microparticles, capsules, or tablets. The method of treatment can be applied to both pediatric and adult patients.
In summary, the patent describes a method for treating PCOS-FOH+FAH using a CRF1 antagonist or a pharmaceutically acceptable salt thereof. The method involves administering the antagonist at various dosage options and results in a reduction of hormone levels associated with the condition. The pharmaceutical composition can be in the form of microparticles, capsules, or tablets, and the treatment can be applied to both pediatric and adult patients.
To know more about GlobalData’s detailed insights on Spruce Biosciences, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
